Dr. Alan Franklin
grew up in Cincinnati, Ohio. He attended Northwestern University as
an undergraduate where he obtained a Bachelor of Science in
Biomedical Engineering, and earned a Varsity Letter in Track.
Dr. Franklin
attended medical school at the Medical College of Ohio/ University
of Toledo. After graduating medical school, Dr. Franklin earned a
PhD at Vanderbilt University in the Department of Molecular
Physiology and Biophysics. His thesis focused upon the molecular
biology of insulin producing cells. Dr. Franklin continued his
training at Vanderbilt as a Medical Intern.
Dr. Franklin
completed his ophthalmology residency at Saint Louis University
where he was chief resident in 1996-1997. He then completed his
training at University of Iowa Hospitals and Clinics for
vitreoretinal diseases and surgery. While at University of Iowa,
Dr. Franklin secured both HEED and HEED-Knapp scholarships.
His research work on an anti-vascular agent as a candidate to treat
retinal diseases such as diabetic retinopathy and age-related
macular degeneration was awarded the best research project by an
ophthalmic physician in training at the 1999 Association of
University Professors in Ophthalmology meeting.
Dr. Franklin has
continued his interest and progress in the treatment of diabetic
retinopathy and age-related macular degeneration (AMD) in his
vitreoretinal practice. He has served as priniciple investigator in
a number of diabetic retinopathy and AMD trials. He has presented
his work at international meetings, and has published multiple
manuscripts on candidate molecules to treat AMD and diabetic
retinopathy. He is a founding member and chief medical officer of
RFE Pharma, and has served on advisory boards for many major
ophthalmic pharmaceutical companies such as Novartis, Alcon, Eyetech,
Pfizer, and QLT.
Dr. Franklin is board certified in ophthalmology.